Healthequity Inc (NASDAQ:HQY) stock has reached a new 52-week high, touching $88.31, signaling strong investor confidence in the health savings account provider. This peak comes amidst a notable year for the company, with the stock price reflecting a significant 1-year change of 16.13%. The surge to the 52-week high represents a culmination of positive sentiment and growth prospects in the health financial services sector, as more consumers and employers focus on health savings and investment solutions.
In other recent news, HealthEquity showcased robust Q2 2025 financial results, reporting a 23% increase in revenue, a 46% rise in adjusted EBITDA, and a 27% surge in Health Savings Accounts (HSAs) assets. The company also completed the final tranche of the BenefitWallet acquisition, adding 216,000 HSAs and $1.0 billion in assets. Additionally, HealthEquity introduced Health Payment Accounts (HPAs) and announced a new $300 million share repurchase program.
RBC Capital Markets and KeyBanc have expressed confidence in HealthEquity's performance. RBC Capital adjusted its price target to $100 from the previous $92, maintaining an Outperform rating. The firm highlighted HealthEquity's HSA growth, custodial cash yields, and service costs as factors driving earnings growth. Similarly, KeyBanc maintained its Overweight rating on the company, emphasizing HealthEquity's resilience in a declining interest rate cycle.
For fiscal 2025, HealthEquity expects revenue to fall between $1.165 billion and $1.185 billion, and adjusted EBITDA to range from $458 million to $478 million. These recent developments underscore HealthEquity's commitment to growth and innovation.
InvestingPro Insights
HealthEquity's recent surge to a 52-week high is supported by solid financial metrics and positive market sentiment. According to InvestingPro data, the company's revenue growth stands at an impressive 17.19% over the last twelve months, with quarterly revenue growth even higher at 23.15%. This robust top-line expansion underscores the increasing adoption of health savings accounts and related services.
InvestingPro Tips highlight that HealthEquity is expected to see net income growth this year, which aligns with the stock's strong performance. The company's liquid assets exceeding short-term obligations suggest a healthy financial position, providing a stable foundation for future growth.
While trading near its 52-week high, HealthEquity maintains a PEG ratio of 0.1, indicating that it may still be undervalued relative to its growth prospects. This could explain the continued investor interest despite the stock's recent gains.
For investors seeking a deeper understanding of HealthEquity's potential, InvestingPro offers 12 additional tips, providing a comprehensive analysis of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.